Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Azirines”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 343 records · Page 19Linked to original sources

AF64A(ethylcholine aziridinium ion)-induced basal forebrain lesion impairs maze performance.

Rats were given bilateral injections of ethylcholine aziridinium ion, AF64A (1 nmol/side) into the basal forebrain (BF). One month later, choline acetyltransferase activity was reduced by 25% in the frontal cortex (FC). There was a marked decrease in cortical uptake of [3H]choline, but [3H]GABA and [3H]dopamine uptake was not affected by the injection. Histological analysis confirmed that this dose of AF64A caused acetylcholinesterase staining in the FC to disappear. Acquisition and retention of a T-maze task were impaired in the rats with BF lesions one month after the injection. Acquisition of the water-filled multiple T-maze task was also impaired by AF64A. These observations suggest that the cholinergic component in the BF is involved in spatial memory.

Acetylcholinesterase↗

Alkylboronic acids accelerate affinity labelling of acetylcholinesterase with N,N-dimethyl-2-phenylaziridinium ion.

The kinetics of acetylcholinesterase alkylation with N,N-dimethyl-2-phenylaziridinium ion, the anionic-site-directed affinity label, has been investigated in the presence of alkylboronic acids, which are known as the esteratic-site-directed reversible inhibitors of the enzyme. The ternary complex of the enzyme, the aziridinium ion and alkylboronic acid, are formed in this reaction. In the case of propylboronic acid, for which the complete kinetic analysis of the acceleration effect has been carried out, the 85-fold increase in the rate of the enzyme alkylation reaction has been found. This acceleration effect was connected with the alkylation step, whereas the non-covalent binding of the aziridinium ion in the enzyme active centre was even hindered by the alkylboronic acid. The possible mechanism of this kinetic acceleration phenomenon is discussed with special reference to the kinetic data for the spontaneous solvolysis reaction of the aziridinium ion in water and organic solvents.

Acetylcholinesterase↗

Pharmacokinetics of 14C-activity after the administration of 14C-azimexone in rats.

The pharmacokinetics of 14C-activity were studied in male Sprague-Dawley rats over 24 and 288 h periods after oral i.v. administration respectively. After oral administration rapid and complete absorption of azimexone occurred. The elimination of radioactivity from plasma after i.v. administration could be best described by an open four-compartment-system yielding a terminal half-life of 74.45 h indicating the existence of deep compartment for azimexone or its metabolites. The renal clearance of 14C-activity decreased considerably after i.v. administration with progressing time. This points to an extensive metabolism of azimexone. Fifty-seven and sixty-seven per cent of the given 14C-activity could be recovered in urine within 24 h after i.v. and p.o. administration respectively and in both cases less than 1% of the doses in feces. Studies on the distribution of the labelled substance 24 h after i.v. administration showed highest concentration in gastric contents, spleen thyroid gland and bone marrow. Twelve days after i.v. administration the ratio of the 14C-content in organ/plasma was greatly increased for spleen, thymus, lung, bone marrow and thyroid gland as compared with the conditions 24 h after administration. Thus it can be assumed that the target organs for the immunomodulating activity of the drug belong to the deep compartment of azimexone or its metabolites.

Adipose Tissue↗

Effect of AF64A on cerebral oxygen consumption in young and old rats.

Regional brain O2 consumption was determined in conscious Fischer-344 rats 3- and 33-months of age after intrahippocampal injection of the selective presynaptic cholinergic neurotoxin AF64A to investigate the influence of acetylcholine on this parameter. Regional cerebral blood flow (rCBF) was determined with 14[C]-iodoantipyrine. Regional arterial and venous oxygen saturation was measured microspectrophotometrically. Regional cerebral oxygen consumption was calculated by multiplying rCBF and cerebral oxygen extraction. Systemic hemodynamic and blood gas parameters were not altered by aging or AF64A. Aging or sham injection per se did not have any significant effect on rCBF, oxygen extraction and cerebral oxygen consumption. In 3-month-old AF64A-treated rats, rCBF, oxygen extraction or cerebral oxygen consumption were significantly lower than in the control group of the same age. Old AF64A-treated animals demonstrated a significant decrease in rCBF and cerebral oxygen consumption but not in cerebral oxygen extraction when compared to the sham-lesioned group of the same age. Oxygen consumption was significantly decreased by AF64A in each examined region of both young and old groups of rats, although the decreases were less severe in the older rats. This may be related to the lesser influence of the cholinergic system on cerebral oxygen consumption in old animals or a decreased toxicity of AF64A in older animals.

Aging↗

Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines.

The physico-chemical properties and immunogenicity of experimental vaccines against foot-and-mouth disease (FMD) and poliomyelitis, prepared by treatment of the viruses with N-acetylethyleneimine (AEI), formaldehyde or neutral red, have been studied. None of these reagents affects the rate of sedimentation of the particles or their reaction with antibody against the major immunogenic sites. FMD vaccines prepared by inactivation with AEI or neutral red, behaved like the untreated virus, in that they were disrupted on lowering the pH below 7. The RNA of the AEI-inactivated virus was degraded into slowly sedimenting molecules. Unlike AEI-inactivated virus, from which all the RNA could be extracted with phenol-SDS, the recovery from the neutral red inactivated virus was variable and was sometimes as low as 40%; this RNA gave a heterogenous profile in sucrose gradients. The capsid proteins in the AEI preparation migrated in SDS-PAGE to the same positions as those of untreated virus, but in the neutral red preparation there was evidence of cross-linking. In contrast, the formaldehyde-inactivated vaccine was stable below pH 7 and the RNA could not be released by extraction with phenol-SDS at pH 5, because the capsid proteins had become cross-linked and/or linked to the RNA. As with foot-and-mouth disease virus (FMDV), poliovirus which had been inactivated with formaldehyde did not release its RNA on extraction with phenol-SDS and the capsid proteins were also cross-linked. Surprisingly, although AEI cleaved the viral RNA slowly in situ, the virus was no longer infectious after 6 h. Neutral red did not reduce the infectivity of the virus. All of the preparations gave similar levels of neutralizing antibody after a single inoculation. The high levels obtained with the formaldehyde-inactivated vaccines have implications for the processing of fixed particles by the antigen-presenting cells.

Animals↗

Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ).

2,5'-Diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ) is an alkylating compound which has exhibited a broad spectrum of antitumor activity against a variety of experimental tumors, particularly those implanted intracranially. We have studied the clinical pharmacology of AZQ in 11 patients with various types of tumors. AZQ was administered at 1-12 mg/m2 daily for 5 days by i.v. infusion in 10-30 min. 14C-labelled AZQ was given on day 1 only. Blood and urine specimens were analyzed radiochemically and chromatographically. The plasma disappearance of unchanged AZQ was essentially biphasic, with an initial plasma t 1/2 of 1.4 +/- 0.4 hr and a terminal t 1/2 of 45.5 +/- 3.1 hr. The apparent volume of distribution was 14.2 +/- 3.0 l/kg. The cumulative urinary excretion of unchanged AZQ was 4.3% in 24 hr and 8.6% in 96 hr. The total clearance of the drug was 200 ml/kg/hr. Cerebrospinal fluid AZQ concentration peaked 45-90 min after drug administration, reaching about 70% of that in plasma, and then declined at nearly the same rate.

Antineoplastic Agents↗

Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.

Forty-two evaluable patients with malignant melanoma received AZQ 27 mg/m2 i.v. every 4 weeks. In 5 patients with poor marrow reserve this dose was reduced to 20 mg/m2. Doses were rapidly escalated when no significant myelosuppression was encountered in previous courses. Twenty-five patients had received no prior chemotherapy. A single partial response was obtained for 3 months. Inconsistent myelosuppression was the main toxic effect in this trial. The median WBC and platelet nadirs were 3200/mm3 (900-19,500) and 105,000/mm3 (33,000-530,000) respectively. In 2 patients leukopenia was complicated by a transient episode of infection. One-third of the patients did not experience significant myelosuppression. Non-hematologic adverse reactions were generally mild to moderate and consisted of nausea and vomiting in 26 patients and alopecia in 1. It is concluded that at this dose schedule AZQ is ineffective against malignant melanoma.

Adult↗

Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule.

Eleven patients with advanced cancer were treated with SOAz, the first aziridino substituted inorganic heterocyclic compound to undergo phase I clinical trials. The agent was administered as a rapid i.v. infusion once a week in a dose of 50, 75 or 100 mg/m2. Severe myelotoxicity, which was prolonged and delayed in onset, precluded continuing treatment for more than three courses in 9 of 11 patients. In two patients thrombocytopenia showed no signs of recovery 9 and 11 weeks after the last infusion. Two minor responses were noted and there was one therapy-related death. Because of severe myelotoxicity, which is cumulative and may be irreversible, this treatment schedule seems unsuitable for phase II studies.

Adult↗

The effect of BM 12.531 (azimexon) on natural killer cell activity in myeloma patients.

The 2-cyanaziridin derivative, azimexon (E), has previously been shown to have certain immunomodulatory properties. In particular, the induction of leukocytosis, the stimulation of delayed-type hypersensitivity reactions and the synergistic effect of azimexon and antibiotics in the control of lethal bacterial and fungal infections in mice prompted us to test azimexon as an adjuvant to chemotherapy in 14 myeloma patients. In a randomized double-blind cross-over study 3 X 600 mg of azimexon were added to one of two consecutive, identical chemotherapy courses consisting of melphalan/prednisone (MP) or vincristine/cyclophosphamide/melphalan/prednisone (VCMP). Chemotherapy was given during days 1-4 and azimexon or placebo were added on days 6, 10 and 14. Blood counts and natural killer (NK) cell testing were performed on days 0 and 21 of each course. With the exception of a transient taste irritation in two patients, azimexon caused no subjective side-effects. White blood cell counts were not altered by the drug; red blood cells and hemoglobin showed a borderline depression after azimexon. NK activities measured against three target cell lines (K562, IGR3, L1210) tended to increase after azimexon treatment. When added in vitro to NK assays azimexon caused a slight increase of NK activity at concentrations of 0.01-0.25 mu/ml, whereas concentrations above 1 microgram/ml were inhibitory. The increase of NK activity by azimexon was not due to the induction of interferon in the effector lymphocyte population.

Adjuvants, Immunologic↗

Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).

The bifunctional cross-linking activity of 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ, NSC 182986) on isolated calf thymus DNA was studied, using ethidium bromide fluorescence assay. Between 1 and 350 microM AZQ produced a dose-dependent cross-linking effect in the presence of a 10-fold excess of sodium borohydride. No cross-linking was observed in the absence of the reducing agent. AZQ can also be activated by NADH and NADPH at pH 4. The AZQ cross-linking activity exhibited a strong pH dependency, highest at acidic pH, lower at alkaline pH and not seen under neutral conditions. It was also significantly inhibited under anaerobic conditions. At pH 5 the binding ratio was 1 molecule of AZQ per 191 bases at an AZQ dose of 300 microM. Our results suggest that reduced AZQ behaved like a bifunctional alkylating agent.

Alkylation↗

Patient motivation and informed consent in a phase I study of an anticancer agent.

In order to evaluate the quality of an informed consent procedure (I.C.P.) 48 patients with advanced cancer were offered participation in a phase I clinical trial and entered an I.C.P. consisting of three separate conversations. In the first session, the possible risks and benefits of a phase I study were informally explained by the patient's personal physician. The second session was attended by the patient, a relative, a registered nurse and a physician; the third session was held at least 5 days after the second. Forty-one patients gave their consent motivated by hope for improvement of their conditions, pressure exerted by relatives and friends, the desire to contribute to the progress of medicine or simply because they felt they had 'no choice'. Encouragement by relatives or friends seems to be a powerful incentive to participate. A period of a few days to consult relatives, friends or trusted physicians as a part of the procedure seems helpful in arriving at a well-considered decision.

Adult↗

The influence of AZQ on the DNA distribution of human cerebral tumours in short-term culture.

The influence of AZQ, a chemotherapeutic agent, on the DNA-distribution of human cerebral tumours in short-term culture was studied by means of a MPV II cytofluorometer. The cell cultures were exposed to increasing concentrations of AZQ during 5 days. The results showed that AZQ has no cell phase-specific activity. The influence on the DNA-distribution varied considerably in the examined tumours. It is hypothesised that the effect of AZQ might depend upon the initial DNA-distribution of human cerebral tumours, hyperdiploid tumours being more vulnerable.

Aziridines↗

Bone marrow toxicity of cyclophosphazenes is related to their structure and the treatment schedule.

For three aziridinyl-substituted inorganic heterocycles belonging to the cyclophosphazene group, the tendency for cumulative bone marrow toxicity was studied in mice. In a one-day regimen, one of these drugs, gem-N3P3Az4Pyr2 (Az = aziridinyl, Pyr = pyrrolidinyl) (AZX), led to an increased death rate after a repeated injection, the number of bone marrow stem cells (CFUgm) being decreased 5 weeks after the second injection of this drug. In a four-day regimen two drugs, (NPAz2)2 NSOAz (Soaz) and AZX, led to an increased death rate after the second treatment course. In surviving animals leucocyte and thrombocyte counts were significantly lower in the second than in the first course. CFUgm counts were decreased for both drugs. For the third drug, trans-N3P3(Az)2(NHMe)4 (AZP), no evidence of cumulative bone marrow toxicity was demonstrated. It is suggested that whereas cytostatic activity of these compounds seems to be comparable, their tendency to cause cumulative marrow toxicity may vary.

Animals↗

Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.

Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.

Adult↗

Renal toxicity of propyleneimine: assessment by non-invasive techniques in the rat.

The nephrotoxicity of three different dose levels of propyleneimine (10, 20 and 30 microliter/kg body wt) administered intraperitoneally to rats was studied and 20 microliters/kg body weight was found to be the most appropriate sublethal dose. Injection of propyleneimine (10 microliters/kg body wt) produced a small rise in N-acetyl-beta-D-glucosaminidase (NAG) activity, minor histological damage but no change in urine volume. Six rats were injected with 20 microliters/kg body weight, and urine was collected over the following 16 days. An immediate increase in urine volume, osmolality together with a concomitant decrease in specific gravity, was accompanied by a small increase in creatinine excretion and a more marked increase in the sodium and potassium content of urine after the administration of the nephrotoxin. NAG activity increased immediately and peaked on day 3, the activity remained elevated until day 12 when it fell to near normal levels. The activity of both beta-D-galactosidase and beta-D-glucosidase increased 9 days after administration of the nephrotoxin. In contrast, no consistent change was found in the excretion of the brush border marker enzymes, leucine aminopeptidase (LAP), alanine aminopeptidase (AAP) or alkaline phosphatase (ALP). Proteinuria increased sharply the day after injection and remained abnormal. Increased urinary albumin excretion and the predominance of low molecular weight proteins was demonstrated by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. Evidence is presented that propyleneimine exerts its early toxic effect on the renal papilla.

Acetylglucosaminidase↗

The neurotoxicity of ethylcholine mustard aziridinium (ECMA) in rat brain reaggregate cultures.

The cholinergic neurotoxin ECMA causes a biphasic loss of choline acetyltransferase activity in foetal rat whole brain reaggregate cultures. Initial direct inhibition is followed by longer-term loss of cholinergic neurones. Final muscarinic receptor binding, neurofilament protein and Na+, K+-ATPase concentrations suggest that the lesion is specific for cholinergic neurones at 12.5 microM ECMA, but is more generalised at 50 microM ECMA.

Animals↗